BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34604920)

  • 1. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival Outcome.
    Yu SCH; Hui JW; Li L; Cho CC; Hui EP; Chan SL; Yeo WM
    Cardiovasc Intervent Radiol; 2022 Feb; 45(2):172-181. PubMed ID: 34604920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score-Matched Study.
    Yu Q; Thapa N; Karani K; Navuluri R; Ahmed O; Van Ha T
    J Vasc Interv Radiol; 2022 Dec; 33(12):1570-1577.e1. PubMed ID: 36100064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
    Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
    Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
    Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective Tumor Response of Hepatocellular Carcinoma Obtained by Transarterial Radioembolization with Iodine-131-Lipiodol Versus Transarterial Chemoembolization for Patients with and without Portal Venous Thrombosis: A Controlled Interventional Trial.
    Oliveira Ribeiro MC; Moda KA; Alvarez M; Koga KH; Moriguchi SM; Carvalho FC; Pinheiro RSN; Qi X; Romeiro FG
    Acad Radiol; 2024 May; 31(5):1839-1848. PubMed ID: 38016824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
    Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
    Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
    Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
    Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.
    Yu SC; Hui JW; Hui EP; Chan SL; Lee KF; Mo F; Wong J; Ma B; Lai P; Mok T; Yeo W
    Radiology; 2014 Feb; 270(2):607-20. PubMed ID: 24126369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry.
    Hund HC; Du L; Matsuoka L; Sze DY; Kennedy AS; Golzarian J; Gandhi RT; Collins ZS; Brown DB
    J Vasc Interv Radiol; 2023 Dec; 34(12):2147-2154.e2. PubMed ID: 37657500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
    Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
    Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective.
    Narayanan A; Garza-Berlanga A; Lopera J
    Ann Palliat Med; 2023 Nov; 12(6):1244-1259. PubMed ID: 37574584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local recurrence following a complete radiologic response in hepatocellular carcinoma patients: comparison of transarterial chemoembolisation and transarterial radioembolisation.
    Young S; Sanghvi T; Ragulojan R; Torkian P; Todatry S; D'Souza D; Flanagan S; Golzarian J
    Clin Radiol; 2024 May; 79(5):371-377. PubMed ID: 38341344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.